Miss Dayna Nicole Portnoy, NP Registered Nurse - General Practice Medicare: Not Enrolled in Medicare Practice Location: 1200 Central Ave, Suite 200, Wilmette, IL 60091 Phone: 847-256-1705 |
Miyeita Giselle Magee, NP Registered Nurse Medicare: Medicare Enrolled Practice Location: 3232 Lake Ave Ste 330, Wilmette, IL 60091 Phone: 224-266-9420 |
Mrs. Faith Mitchel Fairclough, RN BSN IBCLC Registered Nurse - Lactation Consultant Medicare: Not Enrolled in Medicare Practice Location: 2019 Thornwood Ave, Wilmette, IL 60091 Phone: 847-867-3218 |
News Archive
Many are aware that hair loss is a common side effect associated with chemotherapy. However, another albeit common late side effect of cancer treatment is the abnormal swelling of one or more limbs, known as lymphedema. Lymphedema is most commonly the result of an obstruction or disruption of the lymphatic system that occurs immediately after cancer treatment or 1-5, even 20 years after.
Sigma-Aldrich Corporation announced today it has entered into a new gene editing partnership with the University of Michigan Medical School's Vector Core. Under the partnership, Sigma-Aldrich will provide the Vector Core with Sigma CRISPR technology, experimental design consultation, and dedicated gene editing bioinformaticians.
Human herpesvirus 6 (HHV-6) infects nearly 100 percent of humans in early childhood, and the infection then lasts for the rest of a person's life. Now, a team led by Peter Medveczky, MD, a professor in the Department of Molecular Medicine at the University of South Florida, has discovered that in some individuals, HHV-6 causes such a permanent infection by inserting or "integrating" its DNA into human chromosomes.
The Excited State Quantic Chemistry group of the Institute of Molecular Science of the Scientific Park of the University of Valencia, is taking part in a project that has identified a new photolysis process of atmospheric mercury, which modifies how it is transported and deposited in terrestrial ecosystems.
A recent large German study has shown that a new combination therapy for breast cancer treatment leads to a lowered risk of the disease coming back. A commentary on this landmark clinical trial has been published in the latest issue of the Journal of Clinical Oncology by the researchers Masey Ross and Charles Geyer Jr. from the VCU Massey Cancer Center. The commentary was titled, "Nab-Paclitaxel: A New Standard of Care in Neoadjuvant Therapy of High-Risk Early Breast Cancer?"
› Verified 6 days ago